Cargando…

A Medwatch review of reported events in patients who discontinued rivaroxaban (XARELTO) therapy in response to legal advertising

Detalles Bibliográficos
Autores principales:	Burton, Paul, Peacock, W. Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419767/ https://www.ncbi.nlm.nih.gov/pubmed/28491680 http://dx.doi.org/10.1016/j.hrcr.2016.02.001

Ejemplares similares

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
por: Pisters, R., et al.
Publicado: (2017)

Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database
por: Lehrer, Steven, et al.
Publicado: (2018)

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
por: Duprey, Matthew S., et al.
Publicado: (2019)

No Relationship of Anti-Androgens to Alzheimer’s Disease or Cognitive Disorder in the MedWatch Database
por: Lehrer, Steven, et al.
Publicado: (2018)

Beyond post-marketing research and MedWatch: Long-term studies of drug risks
por: Resnik, David B
Publicado: (2007)

Development of new anticoagulant highly honoured: Bayer’s Xarelto® recognised with 2010 international Prix Galien award
Publicado: (2010)

Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)
por: Ogawa, Satoshi, et al.
Publicado: (2018)

Advertising for People Who Don't Like Advertising
por: Kesselskramer
Publicado: (2012)

Doctors Who Advertise
Publicado: (1890)

Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry
por: Vene, Nina, et al.
Publicado: (2016)

Youth Exposure to Marijuana Advertising in Oregon’s Legal Retail Marijuana Market
por: Fiala, Steven C., et al.
Publicado: (2020)

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
por: Dagenais, Gilles R, et al.
Publicado: (2021)

Global Tanning Bed Advertising: A Comparison of Legal Regulations on Three Continents
por: Mathes, Sonja, et al.
Publicado: (2023)

Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report
por: Płatkowska-Adamska, Bernadetta, et al.
Publicado: (2022)

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
por: Dragoni, Francesco, et al.
Publicado: (2018)

Health-Related Content of TV and Radio Advertising of Dietary Supplements—Analysis of Legal Aspects after Introduction of Self-Regulation for Advertising of These Products in Poland
por: Wierzejska, Regina Ewa, et al.
Publicado: (2022)

An International Who's Who legal series
por: Law Business Research Limited. London
Publicado: (2000)

Advertisers and Advertising
Publicado: (1905)

Low-dose rivaroxaban: can cardiovascular events be reduced?
por: De Luca, Leonardo
Publicado: (2023)

Advertising Patterns of internet-Based Male Sex Workers Who Have Sex With Men (MSMSW): The Association Between LGBTQIA+ Events and Advertising for Work During the 2022 Pride Season
por: Jackson, Kristopher J., et al.
Publicado: (2023)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
por: Kishi, Taro, et al.
Publicado: (2021)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility?
por: Naik, Nithesh, et al.
Publicado: (2022)

Advertising at the Crossroads (RLE Advertising)
por: Geller, Max
Publicado: (2013)

Commercial Advertising (RLE Advertising)
por: Russell, Thomas
Publicado: (2013)

Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?
por: Kemp, Anna, et al.
Publicado: (2014)

A Ghost in Coronary Artery – Coronary Artery Embolism After Discontinuation of Rivaroxaban in a Patient With Atrial Fibrillation: Case Report and Review of Literature
por: Abbasi, Danish, et al.
Publicado: (2020)

Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience
por: Agarwal, Ajay, et al.
Publicado: (2013)

Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy
por: Jose, Sophie, et al.
Publicado: (2014)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
por: Patel, Manesh R., et al.
Publicado: (2018)

Legal thesaurus
por: Burton, William C.
Publicado: (1992)

PATIENTS WHO DISCONTINUE DAY HOSPITALISATION - AN ANALYSIS
por: Gopinath, P.S., et al.
Publicado: (1987)

Rivaroxaban: Haemoptysis: case report
Publicado: (2020)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Advertisement
Publicado: (1848)

Advertisements
Publicado: (1943)

Advertisement
Publicado: (1825)

Advertisement
Publicado: (1805)

Advertising
por: Sexton, H. C.
Publicado: (1898)

Cannot write session to /tmp/vufind_sessions/sess_v8rcjb8rem8d8brs06k7o78a8r